{"data": {"id": "scopus_85166397282", "publication_type_id": 5, "publication_type_label": "Artikel i vetenskaplig tidskrift", "ref_value": "ISREF", "title": "Renin-angiotensin system inhibition after surgical aortic valve replacement for aortic stenosis", "pubyear": "2023", "sourcetitle": "Heart", "issn": "13556037", "eissn": null, "sourcevolume": null, "sourceissue": null, "sourcepages": null, "articlenumber": "322922", "abstract": "Objective: The optimal medical therapy after surgical aortic valve replacement (SAVR) for aortic stenosis remains unknown. Renin-angiotensin system (RAS) inhibitors could potentially improve cardiac remodelling and clinical outcomes after SAVR. Methods: All patients undergoing SAVR due to aortic stenosis in Sweden 2006-2020 and surviving 6 months after surgery were included. The primary outcome was major adverse cardiovascular events (MACEs; all-cause mortality, stroke or myocardial infarction). Secondary endpoints included the individual components of MACE and cardiovascular mortality. Time-updated adjusted Cox regression models were used to compare patients with and without RAS inhibitors. Subgroup analyses were performed, as well as a comparison between angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Results: A total of 11 894 patients (mean age, 69.5 years, 40.4% women) were included. Median follow-up time was 5.4 (2.7-8.5) years. At baseline, 53.6% of patients were dispensed RAS inhibitors, this proportion remained stable during follow-up. RAS inhibition was associated with a lower risk of MACE (adjusted hazard ratio (aHR) 0.87 (95% CI 0.81 to 0.93), p<0.001), mainly driven by a lower risk of all-cause death (aHR 0.79 (0.73 to 0.86), p<0.001). The lower MACE risk was consistent in all subgroups except for those with mechanical prostheses (aHR 1.07 (0.84 to 1.37), p for interaction=0.040). Both treatment with ACE inhibitors (aHR 0.89 (95% CI 0.82 to 0.97)) and ARBs (0.87 (0.81 to 0.93)) were associated with lower risk of MACE. Conclusion: The results of this study suggest that medical therapy with an RAS inhibitor after SAVR is associated with a 13% lower risk of MACE and a 21% lower risk of all-cause death.", "keywords": "aortic valve stenosis, clinical, epidemiology, pharmacology", "publication_identifiers": [{"identifier_code": "scopus-id", "identifier_value": "85166397282"}, {"identifier_code": "doi", "identifier_value": "10.1136/heartjnl-2023-322922"}], "authors": [{"affiliations": [{"scopus-afid": "60031699", "scopus-affilname": "Sahlgrenska Universitetssjukhuset", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}, {"scopus-afid": "60027675", "scopus-affilname": "Sahlgrenska Akademin", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}], "person": [{"position": "1", "last_name": "Andreas", "first_name": "Martinsson", "identifiers": [{"type": "orcid", "value": "0000-0003-1461-0777"}, {"type": "scopus-auth-id", "value": "56215957900"}]}]}, {"affiliations": [{"scopus-afid": "60031699", "scopus-affilname": "Sahlgrenska Universitetssjukhuset", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}, {"scopus-afid": "60027675", "scopus-affilname": "Sahlgrenska Akademin", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}], "person": [{"position": "2", "last_name": "Charlotta", "first_name": "T\u00f6rngren", "identifiers": [{"type": "scopus-auth-id", "value": "57990595400"}]}]}, {"affiliations": [{"scopus-afid": "60031699", "scopus-affilname": "Sahlgrenska Universitetssjukhuset", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}, {"scopus-afid": "60027675", "scopus-affilname": "Sahlgrenska Akademin", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}], "person": [{"position": "3", "last_name": "Susanne J.", "first_name": "Nielsen", "identifiers": [{"type": "scopus-auth-id", "value": "55865962300"}]}]}, {"affiliations": [{"scopus-afid": "60006876", "scopus-affilname": "Turun yliopisto", "scopus-affiliation-city": "Turku", "scopus-affiliation-country": "Finland"}, {"scopus-afid": "60002746", "scopus-affilname": "Harvard Medical School", "scopus-affiliation-city": "Boston", "scopus-affiliation-country": "United States"}], "person": [{"position": "4", "last_name": "Emily", "first_name": "Pan", "identifiers": [{"type": "scopus-auth-id", "value": "57195836789"}]}]}, {"affiliations": [{"scopus-afid": "60031699", "scopus-affilname": "Sahlgrenska Universitetssjukhuset", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}, {"scopus-afid": "60027675", "scopus-affilname": "Sahlgrenska Akademin", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}], "person": [{"position": "5", "last_name": "Emma C.", "first_name": "Hansson", "identifiers": [{"type": "scopus-auth-id", "value": "57087543600"}]}]}, {"affiliations": [{"scopus-afid": "60031699", "scopus-affilname": "Sahlgrenska Universitetssjukhuset", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}, {"scopus-afid": "60027675", "scopus-affilname": "Sahlgrenska Akademin", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}], "person": [{"position": "6", "last_name": "Amar", "first_name": "Taha", "identifiers": [{"type": "scopus-auth-id", "value": "57212239901"}]}]}, {"affiliations": [{"scopus-afid": "60031699", "scopus-affilname": "Sahlgrenska Universitetssjukhuset", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}, {"scopus-afid": "60027675", "scopus-affilname": "Sahlgrenska Akademin", "scopus-affiliation-city": "Gothenburg", "scopus-affiliation-country": "Sweden"}], "person": [{"position": "7", "last_name": "Anders", "first_name": "Jeppsson", "identifiers": [{"type": "scopus-auth-id", "value": "7005509590"}]}]}], "source": "scopus", "attended": false}}